Literature DB >> 27251182

Sustainable Financing of Innovative Therapies: A Review of Approaches.

Aidan Hollis1.   

Abstract

The process of innovation is inherently complex, and it occurs within an even more complex institutional environment characterized by incomplete information, market power, and externalities. There are therefore different competing approaches to supporting and financing innovation in medical technologies, which bring their own advantages and disadvantages. This article reviews value- and cost-based pricing, as well direct government funding, and cross-cutting institutional structures. It argues that performance-based risk-sharing agreements are likely to have little effect on the sustainability of financing; that there is a role for cost-based pricing models in some situations; and that the push towards longer exclusivity periods is likely contrary to the interests of industry.

Mesh:

Year:  2016        PMID: 27251182     DOI: 10.1007/s40273-016-0416-x

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  45 in total

1.  Satisfaction guaranteed--"payment by results" for biologic agents.

Authors:  Alan M Garber; Mark B McClellan
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

2.  Value based pricing for NHS drugs: an opportunity not to be missed?

Authors:  Karl Claxton; Andrew Briggs; Martin J Buxton; Anthony J Culyer; Christopher McCabe; Simon Walker; Mark J Sculpher
Journal:  BMJ       Date:  2008-02-02

3.  Global health 2035: a world converging within a generation.

Authors:  Dean T Jamison; Lawrence H Summers; George Alleyne; Kenneth J Arrow; Seth Berkley; Agnes Binagwaho; Flavia Bustreo; David Evans; Richard G A Feachem; Julio Frenk; Gargee Ghosh; Sue J Goldie; Yan Guo; Sanjeev Gupta; Richard Horton; Margaret E Kruk; Adel Mahmoud; Linah K Mohohlo; Mthuli Ncube; Ariel Pablos-Mendez; K Srinath Reddy; Helen Saxenian; Agnes Soucat; Karen H Ulltveit-Moe; Karene H Ulltveit-Moe; Gavin Yamey
Journal:  Lancet       Date:  2013-12-03       Impact factor: 79.321

Review 4.  A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures.

Authors:  John E Brazier; Yaling Yang; Aki Tsuchiya; Donna Louise Rowen
Journal:  Eur J Health Econ       Date:  2009-07-08

5.  Relative effectiveness and the European pharmaceutical market.

Authors:  Bengt Jönsson
Journal:  Eur J Health Econ       Date:  2011-04

6.  The drug push.

Authors:  Kelly Servick
Journal:  Science       Date:  2015-05-22       Impact factor: 47.728

Review 7.  Pragmatic randomized trials in drug development pose new ethical questions: a systematic review.

Authors:  Shona Kalkman; Ghislaine J M W van Thiel; Diederick E Grobbee; Johannes J M van Delden
Journal:  Drug Discov Today       Date:  2015-03-17       Impact factor: 7.851

Review 8.  Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.

Authors:  Scott D Ramsey; Richard J Willke; Henry Glick; Shelby D Reed; Federico Augustovski; Bengt Jonsson; Andrew Briggs; Sean D Sullivan
Journal:  Value Health       Date:  2015-03       Impact factor: 5.725

9.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.

Authors:  Peter J Neumann; Joshua T Cohen; Milton C Weinstein
Journal:  N Engl J Med       Date:  2014-08-28       Impact factor: 91.245

10.  Innovation in the pharmaceutical industry: New estimates of R&D costs.

Authors:  Joseph A DiMasi; Henry G Grabowski; Ronald W Hansen
Journal:  J Health Econ       Date:  2016-02-12       Impact factor: 3.883

View more
  7 in total

Review 1.  Defining and Measuring the Affordability of New Medicines: A Systematic Review.

Authors:  Fernando Antoñanzas; Robert Terkola; Paul M Overton; Natalie Shalet; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2017-08       Impact factor: 4.981

2.  Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges.

Authors:  Deirdre Weymann; Nick Dragojlovic; Samantha Pollard; Dean A Regier
Journal:  J Community Genet       Date:  2019-07-05

3.  The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.

Authors:  Sabine Elisabeth Grimm; Mark Strong; Alan Brennan; Allan J Wailoo
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

4.  The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.

Authors:  Alessandra Ferrario; Diāna Arāja; Tomasz Bochenek; Tarik Čatić; Dávid Dankó; Maria Dimitrova; Jurij Fürst; Ieva Greičiūtė-Kuprijanov; Iris Hoxha; Arianit Jakupi; Erki Laidmäe; Olga Löblová; Ileana Mardare; Vanda Markovic-Pekovic; Dmitry Meshkov; Tanja Novakovic; Guenka Petrova; Maciej Pomorski; Dominik Tomek; Luka Voncina; Alan Haycox; Panos Kanavos; Patricia Vella Bonanno; Brian Godman
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

5.  Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.

Authors:  Rick A Vreman; Thomas F Broekhoff; Hubert Gm Leufkens; Aukje K Mantel-Teeuwisse; Wim G Goettsch
Journal:  Int J Environ Res Public Health       Date:  2020-11-10       Impact factor: 3.390

6.  Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.

Authors:  Olina Efthymiadou; Panos Kanavos
Journal:  BMC Health Serv Res       Date:  2022-08-20       Impact factor: 2.908

7.  Outcome-based reimbursement in Central-Eastern Europe and Middle-East.

Authors:  Ildikó Ádám; Marcelien Callenbach; Bertalan Németh; Rick A Vreman; Cecilia Tollin; Johan Pontén; Dalia Dawoud; Jamie Elvidge; Nick Crabb; Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Anke Pisters-van Roy; Áron Vincziczki; Emad Almomani; Maja Vajagic; Z Gulsen Oner; Mirna Matni; Jurij Fürst; Rabia Kahveci; Wim G Goettsch; Zoltán Kaló
Journal:  Front Med (Lausanne)       Date:  2022-09-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.